Registering for Training and Certification

  1. You have to register for the Certified Methadone Advocate Training course
    through NAMA. The training course is one day. The first training will be at
    the AATOD Conference in Washington on Saturday April 12, 2003. The cost of
    course is $100 and includes 2003 membership in NAMA. Everyone who
    pre-registers and completes the requirements will receive their Patient
    Advocate Training Certificate on the day of the conference. Advocate’s will
    receive their NAMA CPA certification in the
    mail.
  2. Registration for the conference is separate. Contact :American Association for the Treatment
    of Opioid Dependence
    . Unless you need a scholarship then NAMA will
    register you.
  3.  A limited number of scholarships to attend the AATOD conference

    (conference registration and hotel) will be available for advocates 
    through this committee, however you must pay for the Certified
    Methadone Advocate training to qualify. Scholarships for CMA Training itself
    are only available in cases of unusual financial need.

  4. Scholarships are no longer available except for unusual circumstances
    directly through NAMA.
  5. Don’t forget if you want to take the training you have to download a copy
    of the registration form and mail it to NAMA with $100 or or call 212-6979534
    to arrange credit card payment.

    Download
    registration in .pdf
     
        Download registration
    as Word .doc
      
             

    Return to Index

Similar Posts

  • Myths About Methadone by Emmett Velten

    Admin 10/21/2021

    Not just in substance abuse, mental health, and AIDS services do methadone patients face routine discrimination.  San Francisco MUNI will not allow methadone patients to drive its buses, even though an important legal ruling in New York overturned a similar policy (Beazer vs New York City Transit Authority, 1975). Not just in those instances but…

  • Submit a Concern

    Admin 07/03/2021

    Report a Program for NOT Following Federal Recommended Guidelines, COVID-19 Social Distancing and other Protections (for patients and staff) THIS FORM IS IN BETA AND NOT WORKING AT THIS TIME Program Information Name of Program *Name of Program Program Location * Address of ProgramStreet AddressApt, Suite, Bldg. (optional)CityState / Province / RegionPostal / Zip CodeAfghanistanAlbaniaAlgeriaAndorraAngolaAntigua…

  • Hepatitis C Committee

    Admin 06/24/2023

    Chair: Dr. P. Kishore, MD, MPH, CMA (Boston NAMA) Committee Members Paul Bowman, CMA  Cheri Jarvis, CMA  Hepatitis C Hepatitis is an inflammation of the liver. Although in many people the diseased liver is able to repair itself and regain function, it may progress to scarring of the liver and chronic liver disease. Hepatitis can…

  • About TEXNAMA

    Admin 03/17/2022

    Methadone Advocacy: The Time Has Come There are many approaches that a methadone advocacy organization can utilize to bring about change. TexNAMA’s primary objective (as part of NAMA) is the empowerment of patients. By confronting the negative stereotypes TexNAMA works to end the stigma and discrimination that has made recovery and reintegration back into society…

  • Denying Methadone Patients Medical Care

    Admin 04/18/2021

    The bias and misunderstandings about methadone as a medication often result in methadone patients being refused medical care (Umbricht-Schneiter, 1994; Zweben and Sorensen, 1988). Another common scenario is that their medication is used to coerce or manipulate methadone patients into medical treatment (Blansfield, 1992). In other areas of medicine such actions would be considered unethical…

  • The Penal Attitude and Methadone Treatment

    Admin 12/03/2022

    Policy Statement Number 7 January 1997 Methadone treatment has been in existence now for over thirty years returning to society more productive individuals than any other treatment modality. Yet, despite this success it is disparaged and misunderstood which has translated into bias and discrimination not only for the consumer of the treatment as even those…